There is another medical need application of the SUL-compound group with SUL-150, a compound closely related to SUL-238. Recently, a new scientific paper has been published in The International Journal of Molecular Sciences about the potential of SUL-150 as treatment for Pulmonary Arterial Hypertension (PAH) and its comorbidities. PAH is a rare and progressive disease characterized by pulmonary vascular pathologies leading to right ventricular failure with a high mortality rate. Current available treatment options improve quality of life, however these do not mitigate disease progression and some patients who do not respond to these therapies ultimately require a lung transplantation. Mitochondrial dysfunction has been implicated to play an important role in the development and progression of PAH and right ventricular failure. SUL-compounds specifically target the mitochondria, “powerhouses” of cell, and improve their function during disease. The study, performed by Lysanne Jorna, Prof. dr. Rolf Berger, Dr. Guido Krenning and co-authors from the departments of Pediatric and Congenital Cardiology and Clinical Pharmacy and Pharmacology at the University Medical Center Groningen (UMCG), found that treatment with SUL-150 ameliorates pulmonary vascular remodeling and right ventricular failure secondary to PAH. The researchers are hopeful that it could be a promising new treatment option to slow disease progression in PAH and secondary right ventricular failure.
SUL-150 precludes development of right ventricular mitochondrial dysfunction
In this study SUL-150 was tested in a rat model of PAH, reflecting human pathophysiology. Rats received either no treatment, or SUL-150. Treatment with SUL-150 mitigated remodeling of small and large pulmonary arteries, maintained cardiac function and precluded cardiac and cardiomyocyte hypertrophy. Furthermore, SUL-150 therapy improved mitochondrial function in the right ventricle by mitigating loss of mitochondrial DNA, normalizing radical scavenging capacity, decreasing lipid peroxidation and normalizing ATP content. Thus, overall treatment with SUL-150 enhanced mitochondrial health in the right ventricle.
More information
The new publication is available through this link, would you like to receive more information about our compounds or discuss business or collaboration possibilities? Please contact us, we are happy to answer your inquiry!